

In Figure 3(C), in the last line, delete "L.W." and substitute therefor -- L... --.

*In the claims*

Please cancel claims 1-61 without prejudice or disclaimer and enter the following new claims:

*AH*  
~~62.~~ (New) A method of delaying recurrence of a GD2-associated tumor in an individual, comprising administering to the individual an effective amount of an antibody comprising the light and heavy chain variable region sequences contained in SEQ ID NO:2 and SEQ ID NO:4, respectively.

*2/* 63. (New) The method of claim ~~62~~, wherein the GD2-associated tumor is melanoma.

*3/* 64. (New) The method of claim ~~62~~, wherein the GD2-associated tumor is neuroblastoma.

*4/* 65. (New) The method of claim ~~62~~, wherein the GD2-associated tumor is glioma.

*5/* 66. (New) The method of claim ~~62~~, wherein the GD2-associated tumor is sarcoma.

*6/* 67. (New) The method of claim ~~62~~, wherein the GD2-associated tumor is small cell lung cancer.

*7/* 68. (New) The method of claim ~~62~~, wherein said antibody is administered with an adjuvant.

*8/* 69. (New) The method of claim ~~68~~, wherein the adjuvant is aluminum hydroxide.



*Ak*  
*CONT'D.*

9. (New) The method of claim 62, wherein said antibody is administered in an amount of about 1 mg to about 4 mg.

10. (New) The method of claim 62, wherein said antibody is administered in an amount of about 1 mg.

11. (New) The method of claim 62, wherein said antibody is administered in an amount of about 2 mg.

12. (New) The method of claim 62, wherein said antibody is administered at weekly intervals.

13. (New) The method of claim 62, wherein said antibody is administered at bi-weekly intervals.

14. (New) The method of claim 62, wherein said antibody is heat-treated prior to administration.

15. (New) A method of delaying development of a GD2-associated tumor in an individual, comprising administering to the individual an effective amount of an antibody comprising the light and heavy chain variable region sequences contained in SEQ ID NO:2 and SEQ ID NO:4, respectively.

16. (New) The method of claim 15, wherein the GD2-associated tumor is melanoma.

17. (New) The method of claim 16, wherein the GD2-associated tumor is neuroblastoma.

*PA  
cont'd.*

18<sup>29</sup>. (New) The method of claim ~~16~~<sup>15</sup>, wherein the GD2-associated tumor is glioma.

19<sup>30</sup>. (New) The method of claim ~~16~~<sup>15</sup>, wherein the GD2-associated tumor is sarcoma.

20<sup>31</sup>. (New) The method of claim ~~16~~<sup>15</sup>, wherein the GD2-associated tumor is small cell lung cancer.

21<sup>32</sup>. (New) The method of claim ~~16~~<sup>15</sup>, wherein said antibody is administered with an adjuvant.

22<sup>33</sup>. (New) The method of claim ~~16~~<sup>21</sup>, wherein the adjuvant is aluminum hydroxide.

23<sup>34</sup>. (New) The method of claim ~~16~~<sup>15</sup>, wherein said antibody is administered in an amount of about 1 mg to about 4 mg.

24<sup>35</sup>. (New) The method of claim ~~16~~<sup>15</sup>, wherein said antibody is administered in an amount of about 1 mg.

25<sup>36</sup>. (New) The method of claim ~~16~~<sup>15</sup>, wherein said antibody is administered in an amount of about 2 mg.

26<sup>37</sup>. (New) The method of claim ~~16~~<sup>15</sup>, wherein said antibody is administered at weekly intervals.

27<sup>38</sup>. (New) The method of claim ~~16~~<sup>15</sup>, wherein said antibody is administered at bi-weekly intervals.